Literature DB >> 2995392

Tangier disease. The complete mRNA sequence encoding for preproapo-A-I.

S W Law, H B Brewer.   

Abstract

A cDNA library of Tangier liver mRNA has been established, and two apo-A-I-containing clones were identified. The complete derived amino acid sequence of preproapo-A-I has been established by nucleic acid sequence analysis of cloned apo-A-I cDNA and specific primer extensions on Tangier liver RNA. Sequence analysis of the longest cDNA clone, pMDB136T, established the derived amino acid sequence of residues 116-243 of plasma apo-A-I. The remaining portion of the sequence of Tangier preproapo-A-I mRNA was established by sequence analysis of specific primer extensions of synthetic oligonucleotides on Tangier liver mRNA. This latter technique provided the derived amino acid sequence of residues -24 to 116, thus completing the entire preproapo-A-I structure. The structure of Tangier preproapo-A-I was identical to normal preproapo-A-I except for a single base substitution (G----T) which resulted in the isosteric replacement of a glutamic acid residue at position 120 to aspartic acid. These results are interpreted as indicating that there is no major structural defect in Tangier apo-A-I, and the rapid rate of catabolism of apo-A-I in Tangier disease is due to a post-translational defect in apo-A-I metabolism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995392

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

1.  The CpG dinucleotide and human genetic disease.

Authors:  D N Cooper; H Youssoufian
Journal:  Hum Genet       Date:  1988-02       Impact factor: 4.132

2.  In vivo metabolism of proapolipoprotein A-I in Tangier disease.

Authors:  D Bojanovski; R E Gregg; L A Zech; M S Meng; C Bishop; R Ronan; H B Brewer
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

3.  Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease.

Authors:  G A Francis; R H Knopp; J F Oram
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.